BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Regend Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Regend Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07828353-1554@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:REGEND001: Phase 3 readout est. (NCT07828353)
DESCRIPTION:REGEND001\, phase 3\, Chronic Obstructive Pulmonary Disease.\nS
 tudy: A Clinical Study of REGEND001 for the Treatment of Chronic Obstructi
 ve Pulmonary Disease (COPD)\nEstimated primary completion: September 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/regend001#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07828353
URL:https://assetmemo.bio/drug/regend001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
